ECOG-ACRIN Network Group Operations Center

ECOG-ACRIN 网络集团运营中心

• 批准号: 9910963
• 负责人: Peter J ODwyer
• 金额: $ 108.17万
• 依托单位: ECOG-ACRIN MEDICAL RESEARCH FOUNDATION
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-29 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9910963
• 关键词: Adolescent and Young Adult; Adult; Affect; American College of Radiology Imaging Network; Automobile Driving; Bioinformatics; Biological; Biological Assay; Biological Markers; Biometry; Cancer Biology; Cancer Center; Cancer Patient; Cancer Research Network; Cancer Therapy Evaluation Program; Caring; Center for Translational Science Activities; Clinical Markers; Clinical Research; Clinical Trials; Clinical Trials Network; Collaborations; Communities; Community Clinical Oncology Program; Community Practice; Complex; Dana-Farber Cancer Institute; Data; Data Analyses; Databases; Development; Diagnostic Imaging; Discipline; Disease; Early Diagnosis; Eastern Cooperative Oncology Group; Effectiveness; Environment; Evolution; Fostering; Foundations; Funding; Future; Goals; Image; Immunologics; Immunology; Infrastructure; Institutes; International; Intervention; Investigational Therapies; Laboratories; Lead; Leadership; Life; Malignant Neoplasms; Mentorship; Modeling; Monitor; National Clinical Trials Network; Outcomes Research; Participant; Patient Outcomes Assessments; Patient Participation; Patients; Phase II Clinical Trials; Phase III Clinical Trials; Pilot Projects; Population; Positioning Attribute; Prevalence; Public Health; Reporting; Research; Research Personnel; Resources; Risk; Science; Scientist; Site; Specialized Program of Research Excellence; System; Therapeutic; Tissue imaging; Translating; Universities; advanced disease; advocacy organizations; anticancer research; base; biobank; biomarker-driven; cancer clinical trial; cancer therapy; cancer type; care outcomes; career development; comparative effectiveness; data management; data warehouse; experience; imaging study; improved; improved outcome; innovation; member; molecular imaging; multidisciplinary; multimodality; next generation; novel; oncology; operation; programs; quantitative imaging; scientific organization; screening; standard of care; treatment effect

Overall: Publicly-funded cancer clinical trials continue to establish new standards of care and improve outcomes for cancer patients. ECOG-ACRIN (EA) has instituted an organizational matrix based on the integration of biological and imaging studies with clinical trials of novel anti-cancer therapies to conduct cutting-edge clinical research and promote scientific discovery. We have incorporated expertise in imaging, cancer biology and therapy within our scientific organization, working closely with the biostatistics and data management centers at the Dana Farber Cancer Institute and Brown University, to propose a research plan that recognizes the importance of biomarkers to bring precisely targeted clinical trials to broad populations of cancer patients. The EA biorepositories, image databases, immunological laboratories, and associated translational science centers will bring together the correlative science studies that relate cancer biology to clinical markers of treatment effect in a data-rich environment. EA embraces the goals and spirit of the NCTN to conduct science-driven clinical trials to improve the lives of adults with cancer. EA clinical trials are implemented through an efficient operational infrastructure that enables access to cutting-edge treatments across the US from large cancer centers to community practices and assures accrual to complex trials in cancers of varying prevalence. Our science is driven by our membership, which includes the NCI-funded Cancer Centers, the Specialized Programs of Research Excellence (SPOREs), the ETCTN (Experimental Therapeutics Clinical Trials Network), the Quantitative Imaging Network (QIN), the NCTN Lead Academic Participating Sites (LAPS), and the National Community Oncology Research Programs (NCORP). As committed participants in the NCTN and in all aspects of CTEP-led cancer research, EA collaborates across the system to promote and advance the collective efforts of all of the groups. We make available the mentorship and opportunity needed to nourish the next generation of investigators. EA is positioned to make unique contributions to the NCTN, working to translate NCI-supported science into improved outcomes for cancer patients. This model, together with developing innovation in large data analysis, will yield high quality trials that have the potential to be practice-changing, applicable to both academic and community environments, and providing imaging and other biomarkers to identify patients who benefit most.

总体情况： 公共资助的癌症临床试验继续建立新的护理标准， 癌症患者的结果。ECOG-ACRIN（EA）建立了一个基于 生物学和影像学研究与新型抗癌药物临床试验的整合 我们的目标是开展尖端临床研究并促进科学发现。我们有 在我们的科学组织中整合了成像、癌症生物学和治疗方面的专业知识， 与达纳法伯癌症中心的生物统计和数据管理中心密切合作， 研究所和布朗大学，提出一项研究计划，认识到的重要性， 生物标志物，为广大癌症患者群体带来精确靶向的临床试验。的 EA生物储存库、图像数据库、免疫学实验室和相关翻译 科学中心将汇集与癌症生物学相关的相关科学研究， 在数据丰富的环境中评估治疗效果的临床指标。EA拥抱的目标和精神 NCTN将开展科学驱动的临床试验，以改善成年癌症患者的生活。 EA临床试验通过高效的运营基础设施实施， 从大型癌症中心到社区， 实践并确保在不同患病率的癌症中进行复杂试验。我们的科学 是由我们的会员，其中包括国家癌症研究所资助的癌症中心，专业 卓越研究计划（SPOREs），ETCTN（实验治疗学临床） 试验网络），定量成像网络（QIN），NCTN领导学术参与 研究中心（LAPS）和国家社区肿瘤学研究计划（NCORP）。作为 致力于参与NCTN和CTEP领导的癌症研究的各个方面，EA 在整个系统内开展合作，促进和推动所有团体的集体努力。 我们提供所需的指导和机会，以培养下一代， investigators. EA的定位是为NCTN做出独特的贡献， NCI支持的科学用于改善癌症患者的预后。该模型与 在大数据分析方面进行创新，将产生高质量的试验， 改变实践，适用于学术和社区环境，并提供 成像和其他生物标志物，以确定受益最多的患者。